Study Title
AALL1821: Phase 2 Study of Blinatumomab (NSC# 765986, IND# 125462) in Combination with Nivolumab (NSC# 748726, IND# 125462), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged ≥1 to <31 Years Old with First Relapse
Protocol ID
AALL1821
Condition/s
Recurrent B Acute Lymphoblastic Leukemia
Diagnosis Stage
Relapse
Location
NSW, NZ
Sponsor
National Cancer Institute (NCI)
Links
Trial Status
Open
Sites
Starship Children's Hospital
Children's Hospital at Westmead
John Hunter Children's Hospital
Children's Hospital at Westmead
John Hunter Children's Hospital
Study Type
Treatment
Phase
Phase 2
Age Eligibility
1 Year to 31 Years
International registry ID's
NCT04546399
| Study Title | AALL1821: Phase 2 Study of Blinatumomab (NSC# 765986 IND# 125462) in Combination with Nivolumab (NSC# 748726 IND# 125462) a Checkpoint Inhibitor of PD-1 in B-ALL Patients Aged ≥1 to <31 Years Old with First Relapse |
|---|---|
| Protocol ID | AALL1821 |
| Disease (Sub Disease) | Recurrent B Acute Lymphoblastic Leukemia |
| Diagnosis Stage | Relapse |
| Location | NSW / NZ |
| Sponsor | National Cancer Institute (NCI) |
| Links | https://clinicaltrials.gov/ct2/show/NCT04546399 |
| Trial Status | Open |
| Trial Open Date | 04/12/2020 |
| Sites | Starship Children's Hospital/ Children's Hospital at Westmead/ John Hunter Children's Hospital/ |
| Study Type | Treatment |
| Phase | Phase 2 |
| Age Eligibility | 1 Year to 31 Years |
| International registry ID's | NCT04546399 |